Medicenna Reports MDNA11's Compelling Anti-Cancer Activity Is Associated With Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

GlobeNewswireFeb 25 07:00 ET

Medicenna Therapeutics up 12% Following Third-Quarter Results

MT NewswiresFeb 13 11:21 ET

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

GlobeNewswireFeb 13 10:28 ET

Medicenna Therapeutics Corp: INTERIM FINANCIAL STATEMENTSREPORT LETTER FROM FOREIGN ISSUER

SEDARFeb 12 21:00 ET · Announcements

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

GlobeNewswireFeb 5 07:00 ET

Medicenna Reports Updated Data From ABILITY-1 Trial

MT NewswiresDec 5, 2024 08:48 ET